GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030

Market Size & Trends

The global GLP-1 agonists weight loss drugs market size was estimated at USD 13.84 billion in 2024 and is projected to grow at a CAGR of 18.54% from 2025 to 2030. The market for GLP-1 agonist weight loss drugs is experiencing rapid growth, driven by rising obesity rates, increasing health awareness, and strong clinical efficacy of drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound). Pharmaceutical advancements, favorable regulatory approvals, and growing insurance coverage further fuel adoption. In addition, celebrity endorsements and social media influence have heightened consumer demand, expanding the market beyond diabetics to a broader weight management segment.

The increasing prevalence of obesity worldwide is a major driver for the GLP-1 agonist weight loss drugs industry. In 2022, 2.5 billion adults were overweight, including 890 million with obesity, while 37 million children under five were overweight. Key contributors to obesity include poor diet, physical inactivity, and obesogenic environments. However, it is preventable and manageable through healthy eating, regular exercise, and lifestyle changes. The WHO advocates for global action, emphasizing regulations on food and marketing, as well as health sector interventions to address obesity and its associated risks.

According to World Obesity data, global obesity prevalence (BMI ≥30kg/m²) varies significantly, highlighting a strong market potential for GLP-1 agonist weight loss drugs. Countries with the highest obesity rates, such as the United States (40.2%), Kuwait (43.75%), and Mexico (36.9%), present key opportunities for pharmaceutical expansion. South Africa's notable gender disparity, with 41.3% of females and 15.3% of males obese, suggests targeted demand for weight loss treatments. In contrast, lower obesity rates in Japan (4.6%) and India (5.2%) may indicate slower market growth. In Europe, where prevalence ranges from 10.4% in Italy to 20.1% in the UK, and in Asia, where South Korea reports higher male obesity (36.3%) than female (27.6%), demand for GLP-1 agonists weight loss drugs will be shaped by regional and gender-specific obesity trends. These variations emphasize the need for tailored healthcare strategies and policy support to drive the adoption of GLP-1 therapies.

In July 2024, China launched a public awareness campaign to address rising obesity rates, with half of the adult population now overweight or obese—creating a significant market opportunity for GLP-1 agonist weight loss drugs. Led by the National Health Commission, the initiative promotes lifelong weight control through balanced diets, physical activity, quality sleep, and family support. Given obesity's strong link to chronic diseases like cardiovascular issues and diabetes, demand for effective pharmacological interventions, including GLP-1 therapies, is expected to grow. Additionally, government strategies like "15-minute fitness circles" and updated dietary guidelines indicate a broader push for weight management solutions, positioning GLP-1 drugs as a potential complement to lifestyle interventions in China’s evolving healthcare landscape.

Market Concentration & Characteristicstics

The GLP-1 agonists weight loss drugs industry is rapidly evolving with advancements in drug formulations, delivery methods, and combination therapies. Research is focused on enhancing efficacy, reducing side effects, and developing next-generation treatments with longer-lasting effects. Innovations such as oral GLP-1 therapies and dual or triple agonists targeting multiple metabolic pathways aim to improve patient adherence and weight loss outcomes.

Mergers and acquisitions are shaping the GLP-1 weight loss drug industry, with major pharmaceutical companies acquiring biotech firms to strengthen their obesity treatment portfolios. The increasing demand for effective weight management solutions is driving consolidation, with companies seeking to expand production capacity, gain access to novel formulations, and establish a competitive edge in the growing obesity treatment sector.

Regulatory bodies such as the FDA and EMA impose stringent approval processes and safety guidelines for GLP-1 therapies. While these regulations ensure efficacy and patient safety, they also contribute to extended clinical trial timelines and market entry barriers. Reimbursement policies play a crucial role in adoption, as GLP-1 drugs are often high-cost therapies, and insurance coverage significantly impacts patient accessibility, particularly in developing markets.

While the GLP-1 agonists weight loss drugs industry is gaining popularity as a leading pharmacological treatment for obesity, alternative weight-loss interventions exist, including lifestyle modifications, bariatric surgery, and other pharmacotherapies such as GIP/GLP-1 dual agonists or amylin analogs. However, GLP-1 drugs remain a preferred option due to their significant weight reduction benefits, metabolic improvements, and growing physician and consumer acceptance.

Companies are aggressively expanding into high-growth regions such as Asia-Pacific, Latin America, and the Middle East, where obesity rates are rising, and healthcare access is improving. Increasing awareness, policy support for obesity management, and improving insurance coverage are driving market penetration. However, challenges related to affordability, supply chain logistics, and healthcare infrastructure continue to influence the pace of market expansion.

Drugs Insights

Based on drugs, the market has been categorized into Semaglutide (Wegovy), Liraglutide (Saxenda), Tirzepatide (Zepbound), and other drugs. The semaglutide (Wegovy) segment led the market with the largest revenue share of 60.70% in 2024. The Semaglutide market is experiencing rapid growth, driven by its proven efficacy in significant weight reduction and metabolic benefits. With obesity rates rising globally, increasing healthcare awareness, and strong clinical trial results, demand for semaglutide-based treatments like Wegovy and Ozempic continues to surge. Regulatory approvals for chronic weight management, expanding insurance coverage, and growing physician adoption further fuel market expansion. In addition, social media influence, celebrity endorsements, and patient success stories have heightened consumer interest. However, challenges such as high costs, supply shortages, and competition from emerging weight-loss therapies remain.

The Tirzepatide (Zepbound) segment is expected to exhibit at the fastest CAGR over the forecast period, owing to its innovative dual mechanism of action targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In November 2023, the FDA approved Zepbound (tripeptide) for chronic weight management in adults with obesity or overweight, in correspondence with diet and exercise. This weekly injection reduces appetite by activating intestinal hormone receptors. Moreover, clinical trials are further strengthening the drug's applicability and effectiveness in weight loss treatment with associated complications

Route Of Administration Insights

Based on route of administration, the market has been categorized into parenteral and oral. The parenteral segment led the market with the largest revenue share of 92.7% in 2024. The parenteral segment is experiencing strong growth, driven by the high efficacy and bioavailability of injectable formulations. Leading drugs like semaglutide (Wegovy, Ozempic) and tripeptide (Zepbound, Mounjaro) have demonstrated significant weight reduction, fueling demand among patients and healthcare providers. The convenience of once-weekly dosing, improved patient adherence, and advancements in auto-injector technology further support adoption. Regulatory approvals and expanding insurance coverage are also key growth drivers.

The oral segment is expected to exhibit at a significant CAGR over the forecast period. Oral GLP-1 agonist weight loss drugs are gaining traction as a convenient option for the long-term management of obesity, where consistent treatment adherence is essential. Advancements in drug delivery systems have enhanced the appeal of oral formulations, with controlled-release tablets and capsules offering steady therapeutic effects while minimizing common side effects like gastrointestinal discomfort. This innovation provides patients with an easier, non-injectable alternative to traditional parenteral treatments like semaglutide (Ozempic, Wegovy), improving overall patient compliance and satisfaction. As these oral GLP-1 therapies continue to evolve, they are poised to expand the market by making weight management more accessible and convenient for a broader range of individuals.

Distribution Channel Insights

Based on distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and other pharmacies. The retail pharmacies segment led the market with the largest revenue share of 55.46% in 2024. This dominance is driven by increasing consumer demand for accessible, convenient weight loss treatments. As more patients seek solutions for obesity management, retail pharmacies are becoming a key distribution channel, offering easy access to medications like semaglutide (Wegovy, Ozempic) without the need for specialized clinics. Expanding pharmacy services, including consultations, patient education, and home delivery options, are further fueling the adoption of GLP-1 agonists and weight loss drugs. In addition, growing acceptance and coverage by insurance plans, along with increased awareness through retail pharmacy campaigns, are contributing to wider availability.

The other pharmacies are expected to grow at a considerable CAGR over the forecast period. The other pharmacies segment is benefiting from the growing demand for effective weight loss solutions, particularly in specialized healthcare settings such as mail-order pharmacies, compounding pharmacies, and online pharmacies. These pharmacies cater to patients who may require personalized treatment plans, such as those with unique medical conditions or preferences for specific formulations of GLP-1 agonists weight loss drugs like semaglutide (Wegovy, Ozempic). In addition, the rise of telemedicine and online health platforms has increased the accessibility of these medications, allowing patients to receive prescriptions and treatments directly from remote or specialized pharmacies. This segment is becoming increasingly important as patients seek tailored healthcare services, flexible delivery options, and more direct access to weight loss therapies.

Regional Insights

North America dominated the GLP-1 agonists weight loss drugs market with the largest revenue share of 75.50% in 2024. Driven by the increasing prevalence of obesity and related conditions, the demand for GLP-1 agonists, such as Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is rising. The market is also benefiting from a shift toward more accessible treatment options, with both parenteral and oral formulations available in retail and hospital pharmacies.

U.S. GLP-1 Agonists Weight Loss Drugs Market Trends

The GLP-1 agonists weight loss drugs market in the U.S. accounted for the largest market share of 95.23% in North America in 2024. Semaglutide and Tirzepatide have gained significant popularity due to their effectiveness in weight loss, with widespread distribution through hospital pharmacies and retail pharmacies. In addition, the oral formulations of these drugs are gaining traction, making them more accessible to a broader patient base.

Europe GLP-1 Agonists Weight Loss Drugs Market Trends

The GLP-1 agonists weight loss drugs market in Europe is experiencing rapid growth, largely driven by the rising awareness of Semaglutide (Wegovy) and the increasing popularity of other effective GLP-1 therapies such as Liraglutide (Saxenda). These drugs are becoming a preferred option for weight management, particularly in countries like the UK, Germany, and France, where demand is rising steadily. The market growth is being further fueled by the positive reception of GLP-1 agonists among healthcare providers and patients, as well as the increasing prevalence of obesity-related conditions.

The UK GLP-1 agonists weight loss drugs market demand is increasing rapidly as part of efforts to combat rising obesity rates. Semaglutide and Liraglutide are the primary agents used in the market, with both retail and hospital pharmacies playing an essential role in distribution. The growth is also supported by public health initiatives to promote weight management therapies, which are expanding access to these treatments.

The GLP-1 agonists weight loss drugs market in Germany is seeing significant growth in the use of GLP-1 agonists, driven by high demand for Semaglutide and Tirzepatide. Both parenteral and oral formulations are being utilized, with hospital pharmacies and retail pharmacies serving as primary distribution channels. The increase in lifestyle-related conditions like obesity is fueling the growth of these medications, with a rising number of patients seeking effective weight loss treatments.

The France GLP-1 agonists weight loss drugs market is expanding rapidly, particularly for drugs like Semaglutide and Liraglutide, as they offer an effective solution for managing obesity. Hospital pharmacies remain crucial in distributing these therapies, while retail pharmacies are seeing increased access due to government health policies focusing on obesity management.

Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Trends

The GLP-1 agonists weight loss drugs market in Asia Pacific is experiencing notable growth, especially in China, India, Japan, and Australia, due to rising obesity rates and increasing awareness of weight loss treatments. In China, the market is rapidly expanding, with an emphasis on the availability of both parenteral and oral formulations through hospital pharmacies and retail channels. In Japan, Tirzepatide and Semaglutide are gaining popularity, with a strong focus on hospital pharmacies.

The Japan GLP-1 agonists weight loss drugs market is growing, particularly with Tirzepatide and Semaglutide. Hospital pharmacies dominate the distribution, but retail pharmacies are seeing rising demand, especially for oral formulations. The increase in obesity-related diseases and the aging population are key factors driving this demand.

The GLP-1 agonists weight loss drugs market in China is expanding rapidly due to rising obesity rates and increasing healthcare access. Semaglutide and Liraglutide are seeing strong demand in both parenteral and oral formulations, with retail pharmacies and hospital pharmacies playing essential roles in distribution. The rising prevalence of metabolic disorders is a key driver in this growth.

Latin America GLP-1 Agonists Weight Loss Drugs Market Trends

The GLP-1 agonists weight loss drugs market in Latin America is witnessing rapid growth, with increasing awareness about the effectiveness of Semaglutide and Tirzepatide in weight loss. Brazil leads the region where both parenteral and oral formulations are being distributed through hospital pharmacies and retail pharmacies. The increasing demand is driven by rising obesity rates and healthcare system improvements.

The Brazil GLP-1 agonists weight loss drugs market is seeing significant growth in GLP-1 agonist treatments, primarily for Semaglutide and Liraglutide. Hospital pharmacies are crucial distribution points, with an increasing focus on oral formulations. Government initiatives aimed at improving public health and combating obesity are further accelerating the demand for these drugs.

MEA GLP-1 Agonists Weight Loss Drugs Market Trends

The GLP-1 agonists weight loss drugs market in the MEA is experiencing growth due to rising obesity rates and increased awareness about the availability of effective weight loss treatments like Semaglutide. Hospital pharmacies are the leading distributors, with retail pharmacies gradually increasing their market share. Countries like Saudi Arabia and South Africa are experiencing notable demand.

The Saudi Arabia GLP-1 agonists weight loss drugs market is witnessing rapid growth, especially with Tirzepatide and Semaglutide. The increasing prevalence of obesity and lifestyle-related diseases is driving demand. Hospital pharmacies dominate the market, while retail pharmacies are seeing a rise in the distribution of both parenteral and oral formulations, supported by government health initiatives like Vision 2030.

Key GLP-1 Agonists Weight Loss Drugs Company Insights

Leading players in the GLP-1 agonists weight loss drugs industry include Novo Nordisk (Semaglutide), Eli Lilly (Tirzepatide), and other pharmaceutical giants. These companies are focused on enhancing the availability of oral formulations and expanding their distribution channels, including hospital and retail pharmacies, to meet the growing demand for weight loss treatments across different regions. Research and innovation, along with regulatory approvals, will continue to be key drivers for these companies to maintain competitive advantages.

Emerging companies in the GLP-1 agonists weight loss drugs industry are exploring niche areas, including personalized weight loss therapies that cater to specific patient needs. Novel delivery mechanisms, such as sublingual tablets or extended-release formulations, are also being developed to offer more convenient options for patients. These innovations aim to address unmet medical needs, particularly in markets with lower treatment access or where injection-based therapies face adoption challenges.

Recent Developments

• In March 2024, Novo Nordisk’s Wegovy (semaglutide) received FDA approval to reduce the risk of serious cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with cardiovascular disease and obesity or overweight. This makes Wegovy the first weight loss medication approved for this purpose. The approval is based on clinical trial results showing that Wegovy significantly lowers the risk of major cardiovascular events compared to placebo.

• In November 2024, Rhythm Pharmaceuticals presented new data at ObesityWeek 2024, showcasing setmelanotide's effectiveness in treating hypothalamic obesity, MC4R pathway diseases, and pediatric obesity. The data highlighted significant BMI reductions, improved hunger scores, and favorable body composition changes. Additionally, genetic testing revealed associations between obesity and specific genetic variants.

• In November 2023, Eli Lilly and Company’s Zepbound (tirzepatide) was approved by the FDA on November 8, 2023, for chronic weight management in adults with obesity or overweight and weight-related conditions. Administered weekly, Zepbound significantly reduced body weight in trials. Adverse effects include nausea and constipation. It is not recommended for those with certain thyroid or pancreatic conditions.

GLP-1 Agonists Weight Loss Drugs Market Report Scope

Global GLP-1 Agonists Weight Loss Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global GLP-1 agonists weight loss drugs market report based on the drug, route of administration, distribution channel, and region:

• Drugs Outlook (Revenue, USD Million, 2018 - 2030)

  • Semaglutide (Wegovy)

  • Liraglutide (Saxenda)

  • Tirzepatide (Zepbound)

  • Other Drugs

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Parenteral

  • Oral

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Other Pharmacies

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait